ArticleTherapeutic advances in medical oncology2021

Newly developed dual topoisomerase inhibitor P8-D6 is highly active in ovarian cancer.

Inken Flörkemeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.